Navigation Links
Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
Date:6/6/2013

DUBLIN, June 6, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/32gm2w/adult_and) has announced the addition of the "Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


Protection from Cervical Cancer Hindered by Market Rivalry

Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs, states a new report by research and consulting firm GBI Research.

The new report* shows that existing cervical cancer vaccines, GSK's Cervarix and Merck's Gardasil, are competing against each other for valuable market share in a highly rewarding market segment.

The global vaccines market is highly fragmented, and national health authorities can have dramatically differing requirements and regulations, delaying the introduction of some vaccines across global markets. The inclusion of any vaccine into a national immunization schedule promises widespread immunization coverage for the population, and increases the potential for huge revenues for the company.

Despite the European Commission approving Cervarix in 2007, the vaccine was only approved in the US two years later, resulting in a monopoly for competing vaccine Gardasil in the US during this period. Gardasil has also now been approved for use in men to prevent genital warts and anal cancer caused due to human papillomavirus infection, providing the drug with a further strength against competing products.

Cervical cancer vaccines are essentially prophylactic vaccines that prevent against the infection of HPV, which is responsible for 70% of cervical cancer cases in women. HPV vaccines have been found to reduce the incidence of cervical cancer, an area with a high disease burden, and various countries are consequently offering vaccinations for all young girls as a widespread preventative measure. In addition to this, the Advisory Committee on Immunization Practices (ACIP) now also recommends that all 11-12 year old males get vaccinated against HPV, as this will decrease the risk for male genital warts, and reduce the potential for HPV transmission in the future.

Various other high-burden diseases are still urgently in need of vaccines, with HIV/AIDS, malaria and tuberculosis representing some of the most pressing health concerns of many governments across the world. HPV vaccines may herald a new era of preventative medicine, as major diseases are stopped before they ever start.

The Human Papillomavirus (HPV) vaccines market for adults and adolescents across the US, Germany, Spain, Italy, France, the UK and Japan is expected to grow from a strong value of US$1.8 billion in 2011 to US$2.2 billion in 2018. Revenue from HPV vaccines peaked in 2008, following the initiation of nationwide immunization programs, but the anticipated treatment of all children and the high cost of HPV vaccinations, at over US$100 per person, secures this market's future."

Companies Mentioned

- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi

For more information visit http://www.researchandmarkets.com/research/32gm2w/adult_and

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716


Sector: Healthcare and Medical Devices


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Washington State Medical Association (WSMA) Urges Adults to Get Recommended Immunizations
3. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
4. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
7. Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults
8. Zarbees Introduces a New Extra Strength Line of Natural Cough Products for Adults and Children 12+ in Time for Cough and Cold Season
9. RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat patients with various intractable diseases
10. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
11. Weight Loss Surgery May Be as Equally Beneficial for Teens as for Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Miami native and local periodontist Dr. John Paul ... never imagined back in 1991 that this journey would have taken me into so ... 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... agile ecosystem and domain expertise for sponsors and CROs to speed clinical ... supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
Breaking Medicine News(10 mins):